Dispatch Bio Secures $216M in Seed and Series A Funding to Advance FLARE Platform for Universal Solid Tumor Therapy

Jul 23, 2025 21:55 CST Updated 21:55

Dispatch Bio

Immuno-oncology Researcher

ARCH Venture Partners

Venture Capital Firms

PICI

The Parker Institute for Cancer Immunotherapy brings together leading scientists, clinicians, and industry partners to generate smarter, more coordinated cancer immunotherapy research outcomes. PICI was designed in collaboration with the world’s foremost researchers, physicians, and cancer centers, with the aim of removing these barriers and translating cancer research concepts into real-world results.

Bristol-Myers Squibb

Biopharmaceutical and Nutritional Product R&D and Sales

University of Pennsylvania

The University of Pennsylvania is a private Ivy League research university located in Philadelphia, Pennsylvania. It is one of the nine colonial colleges founded before the Declaration of Independence and was the first institution of higher education in the United States to call itself a university.

Stanford University

One of the World's Leading Teaching and Research Universities

July 24, 2025

eMedClub News

On July 23 local time, a new biotechnology company, Dispatch Bio, officially appeared and announced the completion$216 Million in Seed and Series A Funding, co-led by ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy (PICI), with participation from Bristol-Myers Squibb (BMS), the University of Pennsylvania, Stanford University, and other institutions.

This company, founded in 2022, with itsThe First FLARE Immunotherapy Platform, aiming to overcome the two core challenges in solid tumor treatment——Loss of Tumor-Specific Targets and Immunosuppressive Microenvironment, is expected to provide for patients with solid tumors, which account for 90% of total cancer incidence.「Universal Type」Treatment Solutions Inject Disruptive Power into the Immunotherapy Track.

Star-Studded Team and Cutting-Edge Technology Endorsement: Four Scientific Titans' Interdisciplinary Breakthroughs

The birth of Dispatch Bio stems from a「Dream Collaboration」: The company isCAR-T Cell Therapy Pioneer Dr. Carl June(Novartis Kymriah Co-developer), co-founded by Dr. Andy Minn, an expert in immune regulation, Dr. Chris Garcia, an authority in protein engineering, and Dr. Kole Roybal, a synthetic biology expert, in deep collaboration with the Parker Institute, integrating breakthrough technologies from the four scientists' laboratories.

"Our core breakthrough lies in identifying the ideal tumor target, one that is expressed only in the patient's tumor cells.Universal Antigen", said Dr. Sabah Oney, CEO of Dispatch Bio, "The FLARE platform combines cell therapy engineering with immune activation technology, enabling precise tumor clearance at the right time and in the right location, which presents a historic opportunity for solid tumor treatment."

Solid tumors have long been a focus of immunotherapy.Hard Bone: The surface of tumor cells lacks specific antigen markers, leading to immune cells「Friend and Foe Indistinguishable」; At the same time, a large number of inhibitory factors in the tumor microenvironment will「Paralysis」Immune Cells. Dispatch Bio's FLARE platform achieves breakthroughs through the following dual mechanisms:

1. General Antigen Labeling: Tagging Tumor Cells with Localization Markers

The FLARE platform delivers a novel universal antigen—Flare—to tumor cells via a viral vector. This antigen is expressed only in epithelial-derived cancer cells, similar to「Fluorescent Labeling」, enabling immune cells to precisely recognize tumors. At the same time, the viral vector can also break through the suppression of the tumor microenvironment, making tumor cells more easily recognized by immune cells.

2. Engineered CAR-T: Powerful and Precise Elimination of Tumor Cells

The next-generation CAR-T cells developed by the company are engineered using cutting-edge technology, demonstrating excellent efficacy and persistence. This enables them to navigate tumors, maintain activity, and eliminate cancer cells marked by Flare.

Source: Company's official website

Strong Capital Bet: The Expectations Behind $216 Million in Financing

This financing sets a record as the largest single investment in the field of solid tumor immunotherapy in 2025, with the investor lineup highlighting the industry's high expectations for the FLARE platform:

ARCH Venture Partners

A top global biopharmaceutical venture capital firm that has incubated unicorns such as Moderna and CRISPR Therapeutics;

Parker Institute for Cancer Immunotherapy

By Sean Parker(Co-founder of Facebook)Established, focusing on translational medicine research;

Bristol-Myers Squibb (BMS)

Immunotherapy giant Bristol-Myers Squibb, whose PD-1 inhibitor Opdivo boasts annual sales exceeding $10 billion, may be hinting at potential future combination therapies through this strategic investment.

「Dispatch's Technology Will Redefine Solid Tumor Treatment」，Sean Parker, founder of the Parker Institute, commented,「By integrating the interdisciplinary achievements of four scientists, we have the first opportunity to achieveGeneral Treatment, which is one of the ultimate goals of immunotherapy.」。

Billions in Solid Tumor Treatment Market Awaiting Activation

Solid tumors account for 90% of global cancer incidence, but existing immunotherapies(such as PD-1 inhibitors)The response rate is only around 20%, indicating a significant unmet demand in the market. According to data from Research Institute of China National Knowledge Infrastructure, the global cellular immunotherapy market size is expected to exceed 50 billion US dollars by 2025, with the proportion of solid tumor treatments increasing from the current 15% to over 40%.

Dispatch Bio plans to use this financing to advance the company’s therapeutic candidates into first-in-human clinical studies and further research, with the first project expected to enter clinical stage by 2026.

"The 'Holy Grail' of Solid Tumor Immunotherapy Is Within Reach," Dr. Oney emphasized, "Dispatch is not only about developing drugs but also building..."Target Discovery - Vector Design - Clinical Translation'The full-chain ecosystem that transforms general immunotherapy from concept to reality.'

Editorial Director | Kathy

Proofread by Kathy

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Recommendation 1

July 24, 15:00-16:00

Development of Exosome Drugs Under ATMP Regulation and In-Depth Analysis of the World's First Exosome Drug

Statement:This article aims to convey industry development information and explore the frontier progress of biopharmaceuticals. The content of the article represents the author's viewpoint and does not represent the position of EurekaMed, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a正规 hospital for medical advice.

Copyright Statement:Welcome to share the article on your personal WeChat Moments. Unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorized reproduction, please leave a message below the article to obtain permission.

Cover image source: internet. If there is any copyright infringement, please contact us for removal.

Dabigatran「Share」、「Like」And「In View」, give me a little recharge~